ESMO Congress 2022
Patients with resected stage II–III CRC may benefit from earlier detection of recurrence, enabling more to receive surgery with curative intent, but further work is needed to determine the most reliable and cost-effective methods of follow-up
Results of a small phase II trial may open up a new option for some patients with leukoplakia, but toxicity of immunotherapy is high and questions remain about its utility in clinical practice
Encouraging clinical activity was reported for fruquintinib and the combination therapy of trastuzumab plus tucatinib in heavily pre-treated patients with manageable safety profiles
New data show promise of targeted treatment combinations in advanced KRAS G12C-mutated colorectal cancer
Although further evidence is needed, targeting mutant KRAS with novel agents and combinations may offer new options for patients with advanced colorectal cancer
Side-effects may occur at unpredictable timepoints during a patient’s treatment journey and even after treatment cessation
Recent evidence shows the potential of immunotherapy to change the treatment landscape of triple-negative breast cancer (TNBC), where historically, chemotherapy has been the only systemic option. But, how do we choose what therapy to give which patients?
The role of neoadjuvant versus adjuvant immunotherapy is no simple comparison but instead involves a complex interplay of factors, based on tumour immune responsiveness, immunotherapy type, combination partners and trial design
IMmotion010, CheckMate 914 and PROSPER miss their primary endpoints: back to square one for adjuvant immunotherapy?